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Objective: To identify human papilloma viruses (HPV) in atheromatous coronary arteries.
Background: Atheromatous arterial disease is primarily an initial inflammatory response
to unknown stimuli. The crucial question is “what causes the initial inflammation in
atheromatous disease?” HPV infections may be relevant as US women with vaginal, high
risk for cancer, HPV infections, are at up to threefold increased risk of cardiovascular
disease as compared with vaginal HPV-negative women. These studies did not include
analyses of HPV in atheromatous coronary arteries.
Methods: Atheromatous coronary arteries were identified and collected from 20
deceased donors. Polymerase Chain Reaction techniques were used to identify HPV
gene sequences. Immunohistochemistry methods were used to identify HPV E7 proteins.
Results: HPV types 16 and 18 were identified in 11 (55%) of 20 specimens. HPV
E7 protein was identified in 10 (50%) of 20 specimens. Positive and negative HPV
identification and HPV E7 expression in coronary smooth muscle cells were significantly
correlated (cc=0.503, p=0.024). The HPV E7 proteins were expressed in smooth
muscle cells and plasma cells, foam cells, and macrophages located in the atheromatous
plaque. HPV E7 proteins were not expressed in infiltrating lymph cells.
Conclusion: HPV gene sequences were identified in 55% of atheromatous coronary
arteries and may have a role in coronary artery disease.
Keywords: atheroma, coronary vessel anomalies, coronary artery disease, human papillomavirus, HPV E7 protein,
inflammation
Introduction
Atheromatous arterial disease begins as an inflammatory disease (1, 2). The crucial question is “what
causes the initial inflammation?” Infectious microorganisms such as Epstein–Barr virus (EBV),
herpes viruses, cytomegalovirus, chlamydia pneumonia, and porphyromonas gingivalis have all
been postulated as having possible roles in atheromatous vascular disease (3).
Human papilloma virus (HPV) infections may be relevant as Kuo and Fujise have demonstrated
that US women with vaginal, high risk for cancer, HPV infections are at approximately threefold
Abbreviations: EBV, Epstein–Barr virus; HPV, human papilloma virus; IHC, immunohistochemistry; PCR, polymerase chain
reaction.
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increased risk of cardiovascular disease as compared with vaginal
HPV-negative women (4). This study of 2,450 women was based
on the US National Health and Nutrition Examination Survey,
2003–2006, and includedHPVanalyses of vaginal swab specimens
and self-reported diagnoses of myocardial infarction and stroke.
However, Kuo and Fujise study did not include analyses of
HPV in atheromatous coronary arteries. As we have not identified
previous studies of HPV in coronary artery disease, we have
conducted a preliminary study of HPV in coronary arteries from
20 deceased donors, all of whom died because of a myocardial
infarction.We show thatHPVgene sequences appear to be present
in up to 55% of atheromatous coronary arteries.
Materials and Methods
Archival formalin-fixed atheromatous coronary arteries were
selected from 10 donors aged below 35 years, and 10 donors aged
35 years and over, from the Department of Forensic Medicine,
Sydney, NSW, Australia. Younger and older age groups were
selected as there may have been differences in the prevalence of
HPVs identified in their coronary arteries. The cause of death for
all 20 donors was a myocardial infarction due to atheromatous
disease (as determined by Forensic Pathologists).
We sought to identify HPV by polymerase chain reaction tech-
niques (PCR). It is important to note that HPV gene sequences in
coronary artery material can be best identified by nested PCR, a
method, which involves two sets of primers, used in two successive
runs of the PCR.
Three HPV-positive and three HPV-negative specimens were
selected from the 20 coronary artery specimens andwere analyzed
by PCR methods in an independent laboratory (QIMR Berghofer
Medical Research Institute) usingmethods as per Antonsson et al.
(5). PCR was repeated once on primary PCR amplicons in these
confirmatory analyses. Different primers from those used at the
University of New South Wales were used in these confirmatory
analyses.
Human papilloma viruses E6 and E7 are part ofHPVoncogenic
mechanisms, which involve the degradation of p53 by HPV E6
protein and the inactivation of the p110RB by HPV E7 protein.
Positive outcomes of immunohistochemistry (IHC) analyses for
these HPV proteins can offer supportive, but not conclusive, evi-
dence with which to identify biologically active HPVs. Antibodies
for the specific identification of HPV E7 proteins have recently
been developed and made available on a commercial basis (6).
This is the first use by IHC analyses using HPV E7 antibodies
to identify these proteins in atheromatous cardiovascular disease.
The HPV E7 antibodies (Cervimax) have been experimentally
shown to be specific (6).
Polymerase Chain Reaction for HPV
Genomic DNA was prepared using a Qiagen DNeasy blood and
tissue kit, with the added step of incubating the paraffin sections
at 120°C for 20min in the ATL buffer before digestion with
proteinase K. A reagent blank extraction control (an extraction
without formalin fixed paraffin embedded – FFPE tissues) was
performed during the DNA extraction procedure. The gDNA
extracts were quantified with a NanoDrop spectrophotometer
(Thermo Scientific). The DNA quality was tested by the amplifi-
cation of a 268-bp fragment of the β-globin gene using primers
G073 (5’-GAAGAGCCAAGGACAGGTAC-3’) and G074 (5’-
CAACTTCATCCACGTTCACC-3’). The HPV genotypes were
identified by BLAST via theUSNational Center for Biotechnology
Information.
Round 1. My11 (50GCACAGGGYCAYAAYAATGG30) to modi-
fied Gp6 (50AATCATATTCCTCTTCATGTC30).
Round 2. Gp5 (50TATTTGTTACTGTKGTWGATAC30) to Gp6
(These primers were degenerated for HPV16 and 18, but are also
capable of bringing up types 3, 11, 12, 45, 58, 73, and 75.)
Negative controls [no DNA (water) and a reagent blank] were
used in parallel with all PCR analyses. Positive control (HPV18)
was DNA extracted from HeLa cells.
Cycling conditions using Hot Start Taq Master Mix kit from
QIAGEN: 95°C 15min 1 cycle followed by 30 s 95°C, 30 s 55°C,
30 s, and 72°C 35 cycles.
Human papilloma virus identification was considered positive
if sequences were identified at least twice in DNA extracted from
the same specimens.
Polymerase Chain Reaction for Epstein–Barr
Virus
Identification of EBV gene sequences by PCR was conducted on
the same genomic DNA extracts as for HPV. The primers were as
described in Glenn et al. (7).
Immunohistochemistry
Standard manual IHC methods were used. The antibodies were
HPV E7 monoclonal “Cervimax” – Valdospan GmbH. Austria
(Catalogue VS 12001L).
The E7 antibody was optimized at 1/100 dilution. E7 proteins
may be identified by Cervimax from a wide range of HPV types
including HPVs 18, 39, 45, 59 of species 7, andHPV 16, 31, 33, 35,
52, 58 of species 9.
Human papilloma virus types 16 and 18 E7 proteins are
detectable in both cell nuclei and cytoplasm. The outcomes were
assessed by the intensity of staining on a scale of 0 and+ to+++.
Cervical cancer tissues were used as positive controls and normal
breast tissues were used as negative controls. IHC with omission
of the E7 antibody was negative.
Statistical Analysis
The correlations between the identification of HPV gene
sequences and the expression of HPV E7 proteins were assessed
with two-tailed Spearman’s non-parametric correlation statistic
using the SPSS statistical package. A two-tailed p value of equal
or less than 0.05 was considered to be statistically significant.
Results
HPV by PCR Analyses
As shown in Table 1, either or both HPV types 16 and 18 were
identified in 11 (55%) of 20 specimens. Both HPV 16 and 18
are high risk for cancer HPV types. The positive control (HPV
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positive HeLa cells) was positive for HPV 16 and 18. The HPV
negative outcomes for nine coronary artery donor specimens
acted as negative controls for the PCR analyses. HPV type 16
sequences identified in an atheromatous coronary artery from a
34-year-old male are shown in Figure 1.
A cross-sectional image of HPV type 16-positive atheromatous
coronary artery disease is shown in Figure 2. This artery is from
a 35-year-old male. The lumen of the coronary artery is almost
completely blocked by atheroma.
Human papilloma virus type 18 was identified in two of the
three HPV-positive coronary artery specimens (all three were
HPV positive at the University of NSW laboratories) by the
independent laboratory.
EBV by PCR Analyses
EBV gene sequences were identified in 6 (46%) of 13 coronary
artery specimens (sound outcomes were not achieved in 7 spec-
imens). This data is not shown in Table 1.
TABLE 1 | HPV sequences and HPV E7 protein expression in atheromatous
coronary arteries from deceased donors selected by age.
Donor Age HPV type HPV E7 in smooth
muscle cells
1 32 Neg 0
2 65 Neg +
3 33 Neg 0
4 27 16/18 +
5 17 Pos +
6 29 Neg +
7 24 Neg 0
8 28 18 +
9 92 16/18 0
10 67 18 0
11 34 16/18 +++
12 33 Neg 0
13 76 16 0
14 71 Pos +
15 49 18 +
16 43 Neg 0
17 59 18 +
18 69 Neg 0
19 35 16 +
20 74 Neg 0
The correlation between positive and negative HPV gene sequence identification and
HPV E7 protein expression in coronary smooth muscle cells is significant (cc=0.503,
p=0.024 two-tailed Spearman non-parametric correlation). 16/18means both HPV types
16 and 18 were identified.
Pos=positive, Neg= negative, HPV E7 by intensity of staining 0, +, ++, +++. There
was insufficient material for HPV sequencing in two positive samples (the amplified PCR
products were visualized on a 1.5% agarose gels).
HPV E7 Protein
Human papilloma virus E7 was identified in 10 (50%) of 20 spec-
imens as shown in Table 1. The correlation between positive and
negative HPV gene sequence identification and HPV E7 protein
expression in coronary smooth muscle cells is statistically signifi-
cant (cc= 0.503, p= 0.024, two-tailed Spearman non-parametric
correlation).
As shown in Figure 3, HPV E7 proteins were expressed in both
atheromatous plaques and smooth muscle cells of atheromatous
coronary arteries. The HPV E7 proteins were also expressed in
plasma cells, foam cells, and macrophages located in the athero-
matous plaque. HPVE7 proteins were not expressed in infiltrating
lymph cells.
Positive HPV E7 protein expression was observed in smooth
muscle cells in the walls of coronary arteries (not in the athero-
matous plaque).
Controls for IHC
It is difficult to obtain normal coronary arteries to act as negative
controls for HPV E7 (Cervimax) antibodies. For this reason, we
have shown images in Figures 4A,B of both positive and negative
HPV E7 expression in atheromatous coronary arteries from two
deceased donors using Cervimax. There were clearly negative
outcomes using HPV E7 Cervimax antibodies in 10 of the 20
atheromatous coronary arteries used in this study.We regard these
as suitable negative controls. As HPVs are involved in over 95% of
cervical neoplasia, cervical specimens with cervical intraepithelial
FIGURE 2 | Cross section of atheromatous coronary artery from a
35-year-old male donor. This is the same specimen in which HPV E7
protein expression is shown in Figure 3.
FIGURE 1 | HPV type 16 sequences identified in an atheromatous coronary artery from a 34-year-old male donor. Reference sequence is from AF 393502.
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FIGURE 3 | HPV E7 protein expression in an atheromatous coronary artery specimen from a 35-year-old male donor. Left: HPV E7 protein expression in
atheromatous coronary smooth muscle cells. Right: HPV E7 protein expression in foam cells (foam cells are lipid laden macrophage cells associated with atheroma)
in the same specimen.
FIGURE 4 | HPV E7 protein expression in coronary atheroma. (A) HPV E7-positive coronary atheromatous plaque; (B) HPV E7-negative coronary atheromatous
plaque [different specimen to (A)]; (C) HPV E7-positive cervical intraepithelial neoplasia (CIN1).
neoplasia provided readily available positive controls for HPV E7
Cervimax antibody. This is shown in Figure 4C. The staining
is virtually identical with the same Cervimax antibody used on
cervical CIN by Faoro et al. (8) who together with Pascale et al.
(6) were the first to demonstrate the specificity of Cervimax
antibodies.
Frontiers in Cardiovascular Medicine | www.frontiersin.org May 2015 | Volume 2 | Article 174
Lawson et al. Identification of human papilloma viruses in atheromatous coronary artery disease
Discussion
In this study, both HPV types 16 and 18 gene sequences have
been identified by PCR analyses in up to 55% of atheromatous
coronary arteries. HPV E7 proteins were identified in 50% of the
20 coronary artery specimens. There was a consistent correla-
tion between the identification of HPV gene sequences and the
expression of HPV E7 proteins in coronary artery smooth muscle
cells. However, the mere presence of HPV in coronary artery
atheromatous plaques does not infer or conclude any mechanistic
role of HPV in atherosclerosis.
Epstein–Barr virus sequences were identified in 46% coronary
artery specimens (data not shown). This observation corroborates
the previous identification of EBV in coronary artery disease (9).
An important limitation of this study is the lack of controls.
This was due to the high prevalence of atheroma in coronary
arteries of potential control donors who died in motor vehicle
accidents.
Polymerase chain reaction amplification techniques are noto-
riously liable to contamination. However, false-positive PCR
outcomes are unlikely as two HPV types were identified. If con-
tamination had occurred, HPVs of the same types and sequences
in amajority of specimens would have been observed. In addition,
HPV type 18 was identified in the same specimens by an inde-
pendent laboratory using different PCR methods and primers.
This is an indication that the findings are valid. The positive
identification of HPV E7 proteins also offers supportive, but not
conclusive, evidence of the validity of the outcomes.
The correlation between the identification of HPV gene
sequences and the expression of HPV E7 proteins in coronary
artery smooth muscle cells is of particular interest. This correla-
tion is specific to smooth muscle cells and not to other types of
cells in atheromatous coronary arteries. It is of particular interest
that positive HPV E7 staining was observed in smooth muscle
cells within the walls of coronary arteries in addition to within
atheromatous plaques. This suggests that HPVs may have influ-
ences within the wall structure of blood vessels. Bonin et al. (10)
have shown that HPV E6 and E7 proteins induce proliferation
of smooth muscle cells in aortic tissues. Given the correlation
between HPV identification and HPV E7 protein expression in
coronary artery smoothmuscle cells, it is possible that HPV exerts
a specific influence on these cells.
The concept that HPV and other infections may have an ini-
tiating role in atheromatous coronary artery disease is biolog-
ically plausible. This view is based on the following evidence:
(i) initially atheromatous arterial disease is primarily an inflam-
matory phenomena (1), (ii) HPV infections commonly elicit a
persistent inflammatory response (11, 12), (iii) HPV genes E6
and E7 can extend the life span and immortalize atheromatous
plaque-derived normal human aortic smooth muscle cells (10),
(iv) there is a positive association between HPV infections and
giant cell arteritis of the temporal artery (13), (v) HPV type 16 has
been identified in vascular endothelial cells adjacent to cervical
cancer (14), and (vi) the E5 protein of HPV type 16 modulates
composition and dynamics of membrane lipids in keratinocytes
(15). Caspases are protein enzymes, which influence cell death
(apoptosis), and have a critical role in vascular inflammation and
development of atherosclerosis (16). Recently, it has been demon-
strated that HPV E6 oncoproteins promote nuclear localization of
active caspase 8 (17).
There are many factors, which contribute to atheromatous vas-
cular disease including low density lipoproteins, cigarette smok-
ing, hypertension, diabetes mellitus, and genetic susceptibility.
The possibility that infections may have a role in atheromatous
vascular disease is highlighted by the long-term pattern of deaths
due to myocardial infarction. Deaths due to acute myocardial
infarction among Western men and women rose dramatically
(from 200 to 300 deaths per 100,000 people per year) between
1920 and 1950 and then fell equally dramatically to the 1980s (18).
These death rates do not parallel dietary changes during the same
period. This pattern of a rapid rise and fall in death rates is typical
of infectious and not dietary influences.
Other viruses may alter lipid metabolism in coronary cells. For
instance, atherosclerotic lesions are induced by infections with
Marek’s disease herpes virus in chickens (19), herpes simplex virus
infections of arterial smoothmuscle cells can lead tomarked accu-
mulation of cholesterol (20), and herpes simplex virus-1 infections
increase binding of low density lipoproteins to arterial smooth
muscle cells (21).
It is commonly accepted thatHPV infections are predominantly
transmitted during sexual activities and that they are confined
to epithelial cells. There is evidence that neither of the notions
is wholly true. HPVs have been repeatedly identified in white
blood cells in circulating blood of normal subjects and patients
with HPV-associated cervical cancer (22). HPVs have been iden-
tified in mucosal cells and saliva of newborn infants and children
(23). In addition to epithelial cells, HPVs have been identified
in glioblastomas, neural structures, and vascular endothelial cells
(20, 24). Accordingly, it is plausible that HPV s may spread by
bloodstream transmission to vascular structures.
When considered together with these many prior observations,
plus the epidemiological evidence that women with HPV genital
infections are at up to threefold increased risk of heart attacks
or stroke, the notion that HPV infections may have an active
role in atheromatous vascular disease is of considerable interest.
However, the data do not exclude the possibility that HPVs in
atheroma and coronary artery smooth muscle cells are merely
opportunistic parasites and not causal.
Our preliminary investigations need to be confirmed,
extended, and evidence of HPV biological activity in coronary
arteries needs to be developed.
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